As per MarkNtel Advisors the Saudi Arabia Diabetes Drug Market size was valued at around USD 2 billion in 2024 and is projected to reach USD 3.4 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 9% during the forecast period (2025-30). The rate of diabetes is intensively increasing in the region which is creating the demand for the drugs. Also, the increasing spending on the healthcare system with government programs and support is further driving the demand for Diabetes drugs in Saudi Arabia. The government has also been focusing on providing insurance coverage for diseases and the incorporation of new technologies for cutting-edge treatment options for diabetes.

In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2026 to 2032, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.

Explore the Insights – Download a Free Sample:  https://www.marknteladvisors.com/query/request-sample/saudi-arabia-diabetes-drug-market.html

Saudi Arabia Diabetes Drug Market Systems Market Segmentation:

By Insulins

• Basal- Market Size & Forecast 2020-2030, USD Million
  • Lantus (Insulin Glargine)- Market Size & Forecast 2020-2030, USD Million
  • Levemir (Insulin Detemir)- Market Size & Forecast 2020-2030, USD Million
  • Toujeo(Insulin Glargine)- Market Size & Forecast 2020-2030, USD Million
  • Tresiba(Insulin Degludec)- Market Size & Forecast 2020-2030, USD Million
  • Basaglar (Insulin Glargine) - Market Size & Forecast 2020-2030, USD Million
• Bolous- Market Size & Forecast 2020-2030, USD Million
  • NovoRapid/Novolog (Insulin Aspart)- Market Size & Forecast 2020-2030, USD Million
  • Humalog (Insulin Lispro)- Market Size & Forecast 2020-2030, USD Million
  • Apidra (Insulin Glulisine)- Market Size & Forecast 2020-2030, USD Million
• Traditional Insulins- Market Size & Forecast 2020-2030, USD Million
  • Novolin/ Actrapid/Insulatard- Market Size & Forecast 2020-2030, USD Million
  • Humulin- Market Size & Forecast 2020-2030, USD Million
  • Insuman- Market Size & Forecast 2020-2030, USD Million
• Biosimilar Insulins- Market Size & Forecast 2020-2030, USD Million
  • Insulin Glargine Biosimilars- Market Size & Forecast 2020-2030, USD Million
  • Human Insulin Biosimilars- Market Size & Forecast 2020-2030, USD Million

By Oral Anti-Diabetic Drugs

• Biguanides- Market Size & Forecast 2020-2030, USD Million
  • Metformin- Market Size & Forecast 2020-2030, USD Million
• Alpha-Glucosidase Inhibitors- Market Size & Forecast 2020-2030, USD Million
• Dopamine D2 receptor agonist- Market Size & Forecast 2020-2030, USD Million
  • Bromocriptin- Market Size & Forecast 2020-2030, USD Million
• SGLT-2 Inhibitors- Market Size & Forecast 2020-2030, USD Million
  • Invokana (Canagliflozin)- Market Size & Forecast 2020-2030, USD Million
  • Jardiance (Empagliflozin)- Market Size & Forecast 2020-2030, USD Million
  • Farxiga/Forxiga (Dapagliflozin)- Market Size & Forecast 2020-2030, USD Million
  • Suglat (Ipragliflozin)- Market Size & Forecast 2020-2030, USD Million
• DPP-4 Inhibitors- Market Size & Forecast 2020-2030, USD Million
  • Onglyza (Saxagliptin)- Market Size & Forecast 2020-2030, USD Million
  • Tradjenta (Linagliptin)- Market Size & Forecast 2020-2030, USD Million
  • Vipidia/Nesina(Alogliptin)- Market Size & Forecast 2020-2030, USD Million
  • Galvus (Vildagliptin)- Market Size & Forecast 2020-2030, USD Million
• Sulfonylureas- Market Size & Forecast 2020-2030, USD Million
• Meglitinides- Market Size & Forecast 2020-2030, USD Million

By Non-Insulin Injection Drugs

• GLP-1 Receptor Agonists- Market Size & Forecast 2020-2030, USD Million
  • Victoza (Liraglutide)- Market Size & Forecast 2020-2030, USD Million
  • Byetta (Exenatide)- Market Size & Forecast 2020-2030, USD Million
  • Bydureon (Exenatide)- Market Size & Forecast 2020-2030, USD Million
  • Trulicity (Dulaglutide)- Market Size & Forecast 2020-2030, USD Million
  • Lyxumia (Lixisenatide)- Market Size & Forecast 2020-2030, USD Million
• Amylin Analogue- Market Size & Forecast 2020-2030, USD Million
  • Symlin (Pramlintide)- Market Size & Forecast 2020-2030, USD Million

By Combination Drugs

• Insulin Combinations- Market Size & Forecast 2020-2030, USD Million
  • NovoMix (Biphasic Insulin Aspart)- Market Size & Forecast 2020-2030, USD Million
  • Ryzodeg (Insulin Degludec and Insulin Aspart)- Market Size & Forecast 2020-2030, USD Million
  • Xultophy (Insulin Degludec and Liraglutide)- Market Size & Forecast 2020-2030, USD Million
• Oral Combinations- Market Size & Forecast 2020-2030, USD Million
  • Janumet (Sitagliptin and Metformin)- Market Size & Forecast 2020-2030, USD Million

By Distribution Channel

• Hospital Pharmacies- Market Size & Forecast 2020-2030, USD Million
• Retail Pharmacies- Market Size & Forecast 2020-2030, USD Million
• Online Pharmacies- Market Size & Forecast 2020-2030, USD Million
• Clinics and Diabetes Centers- Market Size & Forecast 2020-2030, USD Million

By Region

• Northern
• Central
• Southern
• Eastern
• Western

Saudi Arabia Diabetes Drug Market Recent Development:

• ctober 2024: Novo Nordisk A/S announced an agreement with Lifera. Through Lifera’s subsidiary, SaudiBio, the two companies have agreed to localize insulin production in Saudi Arabia.
• August 2024: Boehringer Ingelheim and Alpha Pharma collaborated to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia. Alpha Pharma, aims to combat type 2 diabetes in the Kingdom and is fully aligned with the Kingdom’s Vision 2030 pillars.

Report Delivery Format – Market research reports from MarkNtel Advisors are delivered in PDF, Excel, and PowerPoint formats. Once the payment is successfully processed, the report will be sent to your registered email within 24 hours.

Saudi Arabia Diabetes Drug Market Drivers:

High Prevalence of Diabetes Propelling Market Growth – Due to genetic predispositions and unhealthy lifestyle choices, Saudi Arabia has one of the highest prevalence rates in the world. By 2026, around 24% of the total adult population of Saudi Arabia is expected to have Diabetes which was just around 17.7% in 2021. This rising prevalence is leading the nation to become the 2nd highest in the Middle East and 7th highest globally in diabetes occupancy. An unhealthy lifestyle has resulted in the prevalence of obesity-related problems in Saudi Arabia that majorly pose a threat to several chronic diseases like Type-2 diabetes. An approximate 35.4% of the adult population of Saudi Arabia suffers from obesity. This creates an immense nationwide demand for Diabetes Drugs for the treatment and prevention of diabetes, thereby significantly contributing to the market growth.

Read Full Report: - https://www.marknteladvisors.com/research-library/saudi-arabia-diabetes-drug-market.html

Report Highlights Essential Insights for Strategic Decision-Making

• Detailed market size, share, and forecast analysis
  • In-depth pricing trends and segment-wise cost evaluations
  • Key industry strategies, including innovation, partnerships, and acquisitions
  • Critical value chain analysis and stakeholder profiling
  • Regional import-export market insights and trade flow assessment
  • Thorough competitive benchmarking of top hearing aid manufacturers
  • Identification of new growth opportunities and niche market segments
  • Overview of market trends, drivers, and challenges shaping future demand

Some of the leading players in the Saudi Arabia Diabetes Drug Market are:

• Novo Nordisk A/S
• Takeda
• Pfizer
• Eli Lilly
• Janssen Pharmaceuticals
• Astellas
• Boehringer Ingelheim
• Merck and Co.
• AstraZeneca
• Julphar
• Bristol Myers Squibb
• Novartis
• Sanofi Aventis
• Others

Research Methodology Summary

A systematic approach is used to ensure accurate market insights, combining both bottom-up and top-down methods. Data triangulation validates findings from multiple angles.

Key Steps:

• Define objectives and research design
• Collect data through surveys and interviews
• Analyze and validate data using reliable tools
• Forecast trends and deliver actionable insights

About us:

MarkNtel Advisors is a globally recognized market research and consulting firm delivering intelligence across the healthcare industry, spanning pharmaceuticals, medical devices, healthcare IT, and biotechnology. Our analysts combine domain expertise with innovation tracking to help healthcare organizations improve efficiency and patient outcomes. Through Consulting Services, we assist clients in interpreting insights, designing go-to-market strategies, and adapting to regulatory changes, fostering sustainable growth in the evolving global healthcare ecosystem.

Trending blog:

• https://www.businesssoftwarehelp.com/articles/empowering-global-trade-decisions-how-markntel-advisors-is-redefining-import-export-intelligence-and-market-research-for-the-next-decade
• https://johnryanwork0.wixsite.com/future-trends-market/post/future-trends-of-toys-market
• https://futuremarketanalysiss.blogspot.com/2025/11/water-pump-market-benelux.html.html

Reach Us:

MarkNtel Advisors

Sector 63, Noida, Uttar Pradesh-201301, India

Contact No: +91 8719999009

Email: sales@marknteladvisors.com